Publication: Bioequivalence of indinavir capsules in healthy volunteers
Issued Date
2010-02-01
Resource Type
ISSN
19057415
Other identifier(s)
2-s2.0-77957968642
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Asian Biomedicine. Vol.4, No.1 (2010), 98-101
Suggested Citation
Suvatna Chulavatnatol, Kumthorn Malathum, Sasisopin Kiertiburanakul, Kittisak Sripha, Pojawon Lawanprasert Bioequivalence of indinavir capsules in healthy volunteers. Asian Biomedicine. Vol.4, No.1 (2010), 98-101. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/28794
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Bioequivalence of indinavir capsules in healthy volunteers
Abstract
Background: Indinavir, one component in the HAART regimen, plays an important role in the current treatment of HIV-infection and AIDS. Availability and accessibility of qualified generic indinavir to patients may be the keys for the success of treatment. Objective: Compare the rate and extent of absorption of a generic indinavir formulation with those of an original formulation in healthy Thai volunteers. Method: A randomized, two-period, two-treatment, two-sequence, crossover study with a two-week washout period was performed. A single dose of 2x400 mg indinavir capsules of each formulation was administered to 24 volunteers after an overnight fast. Indinavir plasma concentrations up to 10 hours postdose were determined using high-performance liquid chromatography. Relevant pharmacokinetic parameters were derived and tested for statistically significant differences using ANOVA and criteria of bioequivalence determination were applied. Results: No statistically significant differences were demonstrated for pharmacokinetic parameters including Cmax, Tmax, AUC0-t, and AUC0-8 derived from the two formulations (n=23, p>0.05). The criteria of bioequivalence determination i.e., the 90% confidence intervals on the mean ratio (generic/original formulation) of natural logarithmtransformed values of C max, AUC 0-t and AUC 0-∞ were 86.3-106.5%, 94.0-108.5%, and 93.9-108.5%, respectively. Conclusion: As the mean ratios of C max, AUC 0-t and AUC 0-∞ of the generic and original formulations were entirely within the guideline range of bioequivalence (80.0-125.0%), the two formulations were considered bioequivalent in terms of rate and extent of absorption.